The survival advantage in ERCC1- cohort was confirmed in all subgroups (Figures 3–4) and was independent from primary site (pancreatic head or body/tale), number and site of metastases (lymph nodes-limited disease, liver-limited disease, pluri-metastatic disease) and patients' frailty. This evidence concerns the gene ERCC1 and metastatic neoplasm.